CARsgen Therapeutics Holdings Limited (2171.HK)

4,990 +0,050 (+1,01%) A partir del 01:35PM HKT. Mercado abierto.

CARsgen Therapeutics Holdings Limited

No. 466 Yindu Road
1st Floor Building 2 Xuhui District
Shanghai
China
86 21 6450 1828
https://www.carsgen.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 516

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Zonghai Li M.D., Ph.D.	Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board	2,24M	N/A	1974
Dr. Huamao Wang Ph.D.	Co-Founder, COO & Executive Director	2,27M	N/A	1977
Dr. Hua Jiang	Executive Director	1,13M	N/A	1979
Dr. Hong Ma	Senior Vice President of Clinical Development	N/A	N/A	1972
Dr. Leigh Hsu	Senior Vice President of Business Development	N/A	N/A	1971
Dr. Raffaele Baffa M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1960
Dr. Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	N/A	N/A	1963
Mr. Wing Yat Lui	Company Secretary	N/A	N/A	1990

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.

Gobierno corporativo

El ISS Governance QualityScore de CARsgen Therapeutics Holdings Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.